Idiopathic Inflammatory Myopathies

C. Treatment and Assessment
  • Chester V. Oddis


  • Precise diagnosis is essential and muscle biopsy may identify myositis not responsive to therapy.

  • Autoantibodies define heterogeneous clinical subsets.

  • Steroids are the main pillar of therapy with immuno-suppressive drugs, such as methotrexate and azathio-prine, utilized as steroid-sparing agents.

  • ■ A core set of measures has been developed for assessing disease activity.


Interstitial Lung Disease Connective Tissue Disease Inclusion Body Myositis Mixed Connective Tissue Disease Assess Disease Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262–1273.PubMedCrossRefGoogle Scholar
  2. 2.
    Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary defi nitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281–2290.PubMedCrossRefGoogle Scholar
  3. 3.
    Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607–2615.PubMedCrossRefGoogle Scholar
  4. 4.
    Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J. Rheumatol 1994;21:739–743.PubMedGoogle Scholar
  5. 5.
    Johnston JD, Lloyd M, Mathews JA, et al. Racial variation in serum creatine kinase levels. J Roy Soc Med 1996;89: 462–464.Google Scholar
  6. 6.
    Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004;16: 678–683.PubMedCrossRefGoogle Scholar
  7. 7.
    Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002;29:1897–1906.PubMedGoogle Scholar
  8. 8.
    Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheum Rep 2005;7:99–105.CrossRefGoogle Scholar
  9. 9.
    Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheum Rep 2002;4:434–441.CrossRefGoogle Scholar
  10. 10.
    Brouwer R, Hengstman GJ, Egberts WT, et al. Autoantibody profi les in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116–123.PubMedCrossRefGoogle Scholar
  11. 11.
    Kao AH, Lacomis DH, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209–215.PubMedCrossRefGoogle Scholar
  12. 12.
    Hengstman GJ, Brouwer R, Egberts WT, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositisspecifi c autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69–75.PubMedCrossRefGoogle Scholar
  13. 13.
    Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study. Lancet 2001;357:96–100.PubMedCrossRefGoogle Scholar
  14. 14.
    Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;18: 236–241.PubMedCrossRefGoogle Scholar
  15. 15.
    Villalba L, Hick JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392–399.PubMedCrossRefGoogle Scholar
  16. 16.
    Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetaseassociated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439–2446.PubMedCrossRefGoogle Scholar
  17. 17.
    Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45:1302–1304.PubMedGoogle Scholar
  18. 18.
    Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993–2000.PubMedCrossRefGoogle Scholar
  19. 19.
    Levine TD. Rituximab in the treatment of dermatomyositis: an openlabel pilot study. Arthritis Rheum 2005;52: 601–607.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Chester V. Oddis
    • 1
  1. 1.Department of Medicine, Division of Rheumatology and Clinical ImmunologyUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations